Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 4Leukemia, Myeloid, Acute 4Metastatic Pancreatic Adenocarcinoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Esophageal Neoplasms 1Adenocarcinoma 1

Interventions

Imatinib Mesylate 142nilotinib 94Cyclophosphamide 91fludarabine phosphate 75fludarabine 67Dasatinib 63Mycophenolic Acid 60Whole-Body Irradiation 59Tacrolimus 47Busulfan 45Cyclosporine 36Peripheral Blood Stem Cell Transplantation 35Cytarabine 35Melphalan 30bosutinib 27ponatinib 26Granulocyte Colony-Stimulating Factor 26thymoglobulin 25Thiotepa 25Methotrexate 25Filgrastim 25asciminib 24Antilymphocyte Serum 24Stem Cell Transplantation 22Sirolimus 17Interferon-alpha 16sargramostim 15Cord Blood Stem Cell Transplantation 14Clofarabine 13Bone Marrow Transplantation 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × 4-fluorobenzoyl-TN-14003 × Clear all
NCT02639559 2023-11-07

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Washington University School of Medicine

Phase 2 Completed
50 enrolled 23 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02115672 2016-08-15

Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia

Sheba Medical Center

Phase 1/2 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡